A Randomized, Double Blind, Placebo-Controlled Dose Escalation Study to Investigate the Safety and Pharmacokinetics after Single and Multiple Doses of SLV334 in Sequential Cohorts of Patients with Moderate and Severe Traumatic

Grants and Contracts Details

StatusFinished
Effective start/end date4/6/099/30/11

Funding

  • Solvay Pharmaceuticals: $14,605.00